- •
Preoperative same-day wire localization (WL) using mammography, ultrasound, MR imaging, and computed tomographic (CT) guidance aids surgical excision of nonpalpable breast lesions.
- •
Non–wire localization devices (I125 RSL, SCOUT RADAR, MAGSEED, and RFID) may provide an alternative means to mark and aids surgical excision of nonpalpable breast lesions and axillary lymph nodes up to 5 to 30 days preoperatively under mammography, ultrasound, and CT guidance.
- •
Non–wire deployment systems via MR
Update on Preoperative Breast Localization
Section snippets
Key points
Current procedures
Conservative breast surgical treatment programs rely on image guidance devices and skills of the radiologist and surgeon. Table 1 summarizes various localization methods reviewed by Corsi and colleagues.8 They reported that because no single localization tool or technique proved better for achieving adequate SM, when advantages and disadvantages of each were taken into account, each multidisciplinary surgical team should adopt the most effective localization and margin assessment technique
Types of non–wire devices
Types of non–wire devices are compared in Fig. 5.
Nonradioactive non–wire devices: SCOUT, MAGSEED, and RFID
The nonradioactive non–wire devices are passive and contain no energy source. Nonradioactive device systems are not constrained by regulations for radioactive devices and therefore can be deployed in one facility and removed in another facility.
SCOUT RADAR device
SCOUT is a nonradioactive non–wire localization device that uses infrared light and radar technology. SCOUT was FDA cleared in August 2014 for localization of breast lesions. As of September 2016, SCOUT Radar has been used in more than 5000 patients in more than 75 US facilities.
The 12-mm SCOUT device is deployed via a 16-g needle introduced under imaging guidance 0 to 30 days before surgery. Retracting the release button, rather than pushing forward, to unsheathe the SCOUT, deploys the device.
MAGSEED device
The MAGSEED device was FDA 510(k) cleared in March 2016 for the localization of breast lesions up to 30 days before surgery. Nonresearch, clinical use of MAGSEED has been commercially available in the US since August 2016. Two clinical studies are ongoing, one for lesion localization (NCT03020888) and one for localization of axillary lymph nodes (NCT03038152). MAGSEED is a metal marker which contains iron particles. The dedicated Sentimag probe uses MAGSEED to generate an alternating magnetic
Radiofrequency identification tag
The FDA has approved implantation of radiofrequency tags in humans for the purposes of identification. RFID systems use radio waves to transfer information. A passive tag has no energy source and can communicate a range of information from one serial number to several pages of data. Pending FDA clearance, the 9-mm RFID tag can be deployed 0 to 30 days before surgery through a preloaded sterile 12-g needle similar to biopsy CLIP or RSL (see Fig. 3). When the patient is in the supine surgical
Future opportunities
Future opportunities for non–wire, nonradioactive localization devices require large-scale multi-institutional studies in the United States. Areas for investigation and development may include the following:
- •
Longer-term placement in patients undergoing neoadjuvant treatment
- •
Placement in suspicious axillary lymph nodes
- •
MR-compatible needle introducers
- •
Comprehensive cost-analysis comparison to include device cost, start-up costs, institutional cost of OR delays and cancellations, administrative costs
Summary
The radiologist plays an important role in detection, diagnosis, localization, pathologic correlation, and follow-up management of patients with breast cancer. The preoperative breast localization devices used by the radiologist and the refined definitions of negative SMs impact the multidisciplinary treatment of breast cancer. This article has reviewed the wire and non–wire tools available for image-guided preoperative localization. Non–wire devices provide the benefits of improved efficiency
References (32)
Surgical margins in patients with early stage breast cancer treated with breast conservation therapy
Am J Surg
(2002)- et al.
Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy
Eur J Cancer
(2010) - et al.
ACR appropriateness criteria stage I breast cancer
J Appl Commun Res
(2014) - et al.
Thoracoscopic management of a pericardial migration of breast biopsy localization wire
Ann Thorac Surg
(2009) - et al.
Current status of radioactive seed for localization of nonpalpable breast lesions
Am J Surg
(2010) - et al.
Ipsilateral breast tumor recurrence and survival following lumpectomy and irradiation: pathological findings from NSABP protocol B-06
Semin Surg Oncol
(1992) - et al.
Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer
N Engl J Med
(2002) - et al.
Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer
N Engl J Med
(2002) - et al.
Surgical margins in lumpectomy for breast cancer—bigger is not better
N Engl J Med
(2012) - et al.
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
J Natl Cancer Inst
(1996)
Preoperative localization and surgical margins in conservative breast surgery
Int J Surg Oncol
Pilot study of a new nonradioactive surgical guidance technology for locating non-palpable breast lesions
Ann Surg Oncol
A prospective, single arm, multi-site clinical evaluation of a nonradioactive surgical guidance technology for the location of nonpalpable breast lesions during excision
Ann Surg Oncol
Evaluation of SAVI SCOUT surgical guidance system for localization and excision of nonpalpable breast lesions: a feasibility study
AJR Am J Roentgenol
A prospective clinical study to evaluate the safety and performance of wireless localization of nonpalpable breast lesions using radiofrequency identification technology
AJR Am J Roentgenol
Cited by (118)
Magnetic Localization of Breast Lesions: A Large-Scale European Evaluation in a National Cancer Institute
2023, Clinical Breast CancerComparison of 3 Different Systems for Non-wire Localization of Lesions in Breast Cancer Surgery
2023, Clinical Breast CancerSavi-Scout Radar Localization: Transitioning From the Traditional Wire Localization to Wireless Technology for Surgical Guidance at Lumpectomies
2023, Seminars in Ultrasound, CT and MRICitation Excerpt :Conservative breast surgery or lumpectomy is a common treatment option.2 For nonpalpable breast tumors, imaging-guided localization followed by surgical excision is the current standard of care.3,4 Wire localization (WL) was first introduced in the 1970s.5
Magnetic Seeds: An Alternative to Wire Localization for Nonpalpable Breast Lesions
2022, Clinical Breast Cancer
Disclosure Statement: The author's hospital received research support from Hologic, Inc (IRB MH#2012.048 and MH#2014.036). The author's employer receives research support from Cianna Medical (IRB MH#2016.078). The author has served on a scientific advisory panel for Hologic and Cianna Medical.